Adocia (ADOCY) 67.5500 $ADOCY
Type-1 diabetes (Juvenile Diabetes) Pipeline Review, H2 2015
M2 - Tue Feb 09, 8:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/4jtbk6/type1_diabetes) has announced the addition of the "Type-1 diabetes (Juvenile Diabetes) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type-1 diabetes (Juvenile Diabetes)and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Type-1 diabetes (Juvenile Diabetes)Overview - Therapeutics Development - Pipeline Products for Type-1 diabetes (Juvenile Diabetes)- Overview - Pipeline Products for Type-1 diabetes (Juvenile Diabetes)- Comparative Analysis - Type-1 diabetes (Juvenile Diabetes)- Therapeutics under Development by Companies - Type-1 diabetes (Juvenile Diabetes)- Therapeutics under Investigation by Universities/Institutes - Type-1 diabetes (Juvenile Diabetes)- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Type-1 diabetes (Juvenile Diabetes)- Products under Development by Companies - Type-1 diabetes (Juvenile Diabetes)- Products under Investigation by Universities/Institutes - Type-1 diabetes (Juvenile Diabetes)- Companies Involved in Therapeutics Development Companies Mentioned - 35 of the 100 Companies - 4SC AG - Adocia - AiCuris GmbH & Co. KG - Amarantus Bioscience Holdings, Inc. - Ambrx, Inc. - AntriaBio, Inc. - Aphios Corporation - Araim Pharmaceuticals Inc. - Argos Therapeutics, Inc. - Artery Therapeutics, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Athersys, Inc. - Axxam SpA - Beta-Cell NV - Biocon Limited - Biodel Inc. - Biogenomics Limited - BioLineRx, Ltd. - BioLingus AG - BioTherapeutics Inc. - Boehringer Ingelheim GmbH - Caladrius Biosciences, Inc. - Carlina Technologies SAS - Cellectis S.A. - Compugen Ltd. - Daewoong Pharmaceutical Co., Ltd. - Dance Biopharm Inc. - Diabetology (Products) Ltd - DiaMedica Inc. - Diasome Pharmaceuticals, Inc. - Dompe Farmaceutici S.p.A. - DoNatur GmbH - Effimune SAS - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/4j...1_diabetes
AMBX: (), LLY: 74.43 (-0.48), BIOD: 0.34 (-0.01), CLBS: 0.53 (-0.02), ARGS: 7.50 (+0.47), AZN: 28.96 (-0.68), CGEN: 6.62 (-0.16), ATHX: 2.35 (-0.04)
Type 2 Diabetes Therapeutics Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/82p26k/type_2_diabetes) has announced the addition of the "Type 2 Diabetes - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 2 Diabetesand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Type 2 DiabetesOverview - Therapeutics Development - Pipeline Products for Type 2 Diabetes- Overview - Pipeline Products for Type 2 Diabetes- Comparative Analysis - Type 2 Diabetes- Therapeutics under Development by Companies - Type 2 Diabetes- Therapeutics under Investigation by Universities/Institutes - Type 2 Diabetes- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Type 2 Diabetes- Products under Development by Companies - Type 2 Diabetes- Products under Investigation by Universities/Institutes - Type 2 Diabetes- Companies Involved in Therapeutics Development Companies Mentioned - Sample List - 3SBio Inc. - Addex Therapeutics Ltd - Adocia - Advinus Therapeutics Ltd. - Aegis Therapeutics, LLC - AFFiRiS AG - Alchemia Limited - Alize Pharma SAS - AlphaMab Co., Ltd - Amarantus Bioscience Holdings, Inc. - Ambrx, Inc. - Amgen Inc. - Anchor Therapeutics, Inc. - AntriaBio, Inc. - Aphios Corporation - Araim Pharmaceuticals Inc. - Arisaph Pharmaceuticals, Inc. - ArisGen SA - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Artery Therapeutics, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - AUS Bio Limited - Avaxia Biologics, Inc. - Bayer AG - Beta-Cell NV - Betagenon AB - Biocon Limited - Biodel Inc. - Biogenomics Limited - BioLingus AG - BioRestorative Therapies, Inc. - BioTherapeutics Inc. For more information visit http://www.researchandmarkets.com/research/82...2_diabetes
AMBX: (), AMGN: 156.78 (-1.22), BIOD: 0.34 (-0.01), AZN: 28.96 (-0.68), ARRY: 3.52 (-0.10)
Diabetic Foot Ulcers - Pipeline Review 2015
M2 - Wed Jan 06, 4:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/n92r2c/diabetic_foot) has announced the addition of the "Diabetic Foot Ulcers - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Foot Ulcers, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Foot Ulcers and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Develop strategic initiatives by understanding the focus areas of leading companies. - Identify and understand important and diverse types of therapeutics under development for Diabetic Foot Ulcers. - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Diabetic Foot Ulcers pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - Adocia - Aprogen, Inc. - Bayer AG - CardioVascular BioTherapeutics, Inc. - Celgene Corporation - CoDa Therapeutics, Inc. - CytoTools AG - Dipexium Pharmaceuticals LLC - EyeGene, Inc. - FirstString Research, Inc. - GlaxoSmithKline Plc - Human Stem Cells Institute - Innovaxis - Izun Pharmaceuticals Corporation - Karyopharm Therapeutics, Inc. - Lytix Biopharma AS - MediaPharma s.r.l. - MediWound Ltd. - NovaLead Pharma Pvt. Ltd. - Oneness Biotech Co., Ltd. - Osiris Therapeutics, Inc. - Plurogen Therapeutics, Inc. - Sanofi - Stratatech Corporation - TechnoPhage SA - TGV-Laboratories - Theravasc, Inc. - Tissue Med Biosciences - USV Limited For more information visit http://www.researchandmarkets.com/research/n9...betic_foot
DPRX: 11.42 (+0.11), OSIR: 5.00 (-0.05), MDWD: 8.23 (+0.11), GSK: 42.06 (-0.45), KPTI: 9.12 (-0.17), CELGZ: 1.46 (-0.04)
Global Burns Therapeutics Pipeline Review 2015
M2 - Thu Dec 03, 7:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/phkvtr/burns_pipeline) has announced the addition of the "Burns - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Burns, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Burns and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adocia - AlgiPharma AS - Biogenomics Limited - Birken AG - CytoTools AG - Destiny Pharma Limited - HanAll Biopharma Co., Ltd. - Kuros Biosurgery AG - MediWound Ltd. - Novan, Inc. - Novartis AG - Pherecydes Pharma SA - Phosphagenics Limited - Se-cure Pharmaceuticals Ltd. - Stratatech Corporation - USV Limited - Vida Therapeutics Inc. - Xiber Science GmbH For more information visit http://www.researchandmarkets.com/research/ph...s_pipeline
MDWD: 8.23 (+0.11), NVS: 80.51 (-0.88)
Venous Leg Ulcers (Crural ulcer) Pipeline Review, H2 2015 - 12 Companies & 13 Drug Profiles
M2 - Thu Oct 22, 9:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zpfjm6/venous_leg_ulcers) has announced the addition of the "Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Venous Leg Ulcers (Crural ulcer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Leg Ulcers (Crural ulcer) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adocia - CardioVascular BioTherapeutics, Inc. - CoDa Therapeutics, Inc. - CytoTools AG - FirstString Research, Inc. - Intralytix, Inc. - MacroCure Ltd. - MediWound Ltd. - Pergamum AB - RegeneRx Biopharmaceuticals, Inc. - Smith & Nephew Plc - Stratatech Corporation Drug Profiles - Biochaperone PDGF-BB - Cathelicidin - Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers - CL-05 - CODA-001 - CureXcell - CVBT-141B - EscharEx - Granexin - HP-802247 - LL-37 - RGN-137 - WPP-201 For more information visit http://www.researchandmarkets.com/research/zp...leg_ulcers
SNN: 34.19 (-0.16), MDWD: 8.23 (+0.11)
Human Insulin Market Development and Demand Forecast to 2020 - Provides Information on the Historical and Current Market Size and the Future Potential of the Market
M2 - Thu Aug 20, 5:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fhwk3w/global_industry) has announced the addition of the "Global Industry Insight: Human Insulin Market Development and Demand Forecast to 2020" report to their offering. Increasing usage of insulin pens for the administration of insulin helps to inject insulin accurately. In addition, growing demand of biosimilar drugs due to its cost effectiveness is an opportunity for the growth of the market. Human insulin market is growing moderately due to increase in prevalence of diabetic population, rise in geriatric population, rising awareness of diabetes and rising prevalence of obesity. However, strict regulatory requirements for approval of insulin and high cost of analog are inhibiting the growth of the global human insulin market. Globally, modern human insulin has the largest market share and is also the fastest growing human insulin type. In addition, long acting human insulin has the largest market share in the modern human insulin market, and premixed human insulin is the fastest growing modern human insulin in the market. Long acting human insulin is prescribed by physicians for the treatment of type 2 diabetes. Report Coverage - Provides comprehensive understanding of the market with the help of informed market outlook, opportunities, challenges, trends, size and growth, competitive analysis, major competitors and Porter analysis - Identifies the key drivers of growth and challenges of the key industry players. Also, assesses the future impact of the propellants and restraints on the market - Uncovers potential demands in the market Key Topics Covered: 1 Research Scope and Methodology 2 Executive Summary 3 Market Outlook 4 Global Market Size and Forecasts (2011 - 2020) 5 Global Market Breakdown by Type 6 Global Traditional Human Insulin Market Breakdown by Type 7 Global Modern Human Insulin Market Breakdown by Type 8 Global Market Breakdown by Brand 9 Global Market Breakdown by Region 10 Competitive Analysis and Market Share 11 Company Profiles 12 Appendix Companies Mentioned - ADOCIA - Biocon Ltd. - Bristol-Myers Squibb Company - Eli Lilly and Company - GlaxoSmithKline Plc - Julphar - Merck & Co. - Novo Nordisk A/S - Oramed Pharmaceuticals, Inc. - Pfizer, Inc. - Sanofi - TonghuaDongbao Pharmaceuticals Co., Ltd For more information visit http://www.researchandmarkets.com/research/fh...l_industry
NVO: 56.87 (-0.31), ORMP: 8.55 (+0.50), PFE: 35.31 (+0.06), MRK: 57.18 (-0.44), LLY: 74.43 (-0.48), GSK: 42.06 (-0.45), BMY: 72.73 (-0.68)
Lyonbiopole Announces Success at BIO 2015
Marketwired - Tue Jul 28, 8:02PM CDT
Lyonbiopole, leader in the life science industry, showcased at the BIO International Convention for the ninth consecutive year, celebrating an impressive delegation, influential awards and announcements, and renewed ties with partners on the American East Coast. Participants of the Lyonbiopole mission included Adocia, Alaxia, Alize Pharma, BIOASTER, CapEval Pharma, CEA Leti, Cytoo, ElsaLys Biotech, ERYtech Pharma, Eveon, Flamel Technologies, Genoway, ImmunID, Kallistem, Maat Pharma, Newtone Technologies, Orega Biotech, PDC*line Pharma, TransCure bioServices and Transgene.
Global Market Study on Human Insulin 2015-2020
M2 - Fri Jul 10, 5:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pg6w4q/global_market) has announced the addition of the "Global Market Study on Human Insulin: Asia Pacific to Witness fastest Growth by 2020" report to their offering. Modern human insulin was estimated at USD 19,526.8 million in 2014 and was expected to reach USD 40,987.1 million by 2020, growing at a CAGR of 13.2% during the forecast period. Globally, the human insulin market is witnessing significant growth due to increasing prevalence of diabetes and obesity. In addition, increasing R&D investments in drug discovery and development and rising awareness about diabetes are also driving the growth of the market. However, uneven pricing and limited access to human insulin in emerging countries and strict regulatory requirement for drug approval inhibits the growth of the market. North America has the largest market and Asia-Pacific has the fastest growing market for human insulin. In terms of type of human insulin, modern human insulin represents the largest and fastest growing segment of this market. Modern human insulin provides effective results compare to traditional human insulin. Dosages and duration of modern human insulin vary from person to person, as insulin requirement differs from person to person. Some of the major players in the human insulin market are Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Biocon, Tonghua Dongbao Pharmaceutical Co., Ltd., Adocia, Merck & Co., Inc., Pfizer, Inc., Wockhardt and others. Key Topics Covered: Chapter 1 Preface Chapter 2 Market Synopsis Chapter 3 Porter's Five Forces Analysis Chapter 4 Industry Overview Chapter 5 Global Market Size and Forecast Chapter 6 Market Size and Forecast by Type Chapter 7 Market Size and Forecast of Traditional Human Insulin by Type Chapter 8 Market Size and Forecast of Modern Human Insulin by Type Chapter 9 Market Size and Forecast by Disease Chapter 10 Market Size and Forecast by Brand Chapter 11 Market Size and Forecast by Geography Chapter 12 Pipeline Drugs for Diabetes Treatment Chapter 13 Competitive Scenario Chapter 14 Company Profiles - ADOCIA - Biocon - Bristol-Myers Squibb Company - Eli Lilly and Company - GlaxoSmithKline Plc - Julphar - Merck & Co., Inc. - Novo Nordisk A/S - Oramed Pharmaceuticals, Inc. - Pfizer, Inc. - Sanofi - Tonghua Dongbao Pharmaceutical Co., Ltd. - Wockhardt For more information visit http://www.researchandmarkets.com/research/pg...bal_market
NVO: 56.87 (-0.31), ORMP: 8.55 (+0.50), PFE: 35.31 (+0.06), MRK: 57.18 (-0.44), LLY: 74.43 (-0.48), GSK: 42.06 (-0.45), BMY: 72.73 (-0.68)
Diabetic Foot Ulcers Therapeutics Pipeline Review, H1 2015 - 30 Companies & 44 Drug Profiles
M2 - Thu Jul 09, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7tnfs3/diabetic_foot) has announced the addition of the "Diabetic Foot Ulcers - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Foot Ulcers, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Foot Ulcers and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adocia - Aprogen, Inc. - CardioVascular BioTherapeutics, Inc. - Celgene Corporation - CoDa Therapeutics, Inc. - CytoTools AG - Derma Sciences, Inc. - Dipexium Pharmaceuticals LLC - EyeGene, Inc. - FirstString Research, Inc. - GlaxoSmithKline plc - Innovaxis - Izun Pharmaceuticals Corporation - Karyopharm Therapeutics, Inc. - Kasiak Research Pvt. Ltd. - Lumosa Therapeutics Co., Ltd. - Lytix Biopharma AS - MacroCure Ltd. - MediaPharma s.r.l. - NovaLead Pharma Pvt. Ltd. - Oneness Biotech Co., Ltd. - Plurogen Therapeutics, Inc. - Reliance Life Sciences Pvt. Ltd. - Royer Biomedical, Inc. - Sanofi - Stratatech Corporation - TechnoPhage SA - Tissue Med Biosciences - USV Limited - Vyome Biosciences Private Limited For more information visit http://www.researchandmarkets.com/research/7t...betic_foot
DSCI: 3.99 (-0.03), DPRX: 11.42 (+0.11), GSK: 42.06 (-0.45), KPTI: 9.12 (-0.17), CELGZ: 1.46 (-0.04)
Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2015 Featuring 90+ Companies
M2 - Thu Jun 25, 6:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5gpct9/type_1_diabetes) has announced the addition of the "Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Type 1 Diabetes (Juvenile Diabetes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - 30 of the 93 Companies Featured - 4SC AG - ActogeniX NV - Adocia - AiCuris GmbH & Co. KG - Amarantus Bioscience Holdings, Inc. - Ambrx, Inc. - American Gene Technologies International Inc. - AntriaBio, Inc. - Argos Therapeutics, Inc. - Artery Therapeutics, Inc. - AstraZeneca PLC - Axxam SpA - Bayhill Therapeutics, Inc. - Beta-Cell NV - Biocon Limited - Biodel Inc. - Biogenomics Limited - BioLineRx, Ltd. - BioTherapeutics Inc. - Boehringer Ingelheim GmbH - Carlina Technologies SAS - Cellectis S.A. - Compugen Ltd. - Cortendo AB - CTI BioPharma Corp. - Daewoong Pharmaceutical Co., Ltd. - Diabetology Limited - DiaMedica Inc. - Diasome Pharmaceuticals, Inc. - Dompe Farmaceutici S.p.A For more information visit http://www.researchandmarkets.com/research/5g...1_diabetes
AMBX: (), CTIC: 0.44 (-0.01), BIOD: 0.34 (-0.01), ARGS: 7.50 (+0.47), AZN: 28.96 (-0.68), CGEN: 6.62 (-0.16)
Burns Pipeline Review, H1 2015 - Featuring 19 Therapeutic Companies
M2 - Thu Jun 11, 10:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l85dsl/burns_pipeline) has announced the addition of the "Burns - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Burns, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Burns and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adocia - AlgiPharma AS - Biogenomics Limited - Birken AG - CytoTools AG - Destiny Pharma Ltd. - Fibrocell Science, Inc. - HanAll Biopharma Co., Ltd. - Kasiak Research Pvt. Ltd. - Kuros Biosurgery AG - MediWound Ltd. - Novan, Inc. - Novartis AG - Se-cure Pharmaceuticals Ltd. - Stemnion, Inc - Stratatech Corporation - USV Limited - Vida Therapeutics Inc. - Xiber Science GmbH For more information visit http://www.researchandmarkets.com/research/l8...s_pipeline
FCSC: 1.24 (-0.02), MDWD: 8.23 (+0.11), NVS: 80.51 (-0.88)
Lilly to co-develop ultra-rapid insulin BioChaperone Lispro in partnership with Adocia
M2 - Fri Dec 19, 7:09AM CST
Healthcare company Eli Lilly and Company (NYSE:LLY) and Adocia (Euronext Paris:FR0011184241) jointly disclosed on Thursday a worldwide licensing collaboration to develop an ultra-rapid insulin, called BioChaperone Lispro, for treatment in people with type 1 and type 2 diabetes.
LLY: 74.43 (-0.48)
Eli Lilly reaches insulin development deal with Adocia
AP - Fri Dec 19, 6:16AM CST
INDIANAPOLIS (AP) — Eli Lilly and Co. could pay more than $570 million to French pharmaceutical company Adocia under an agreement to develop a fast-acting insulin that is in the early stages of clinical testing.
LLY: 74.43 (-0.48)
Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology
PR Newswire - Fri Dec 19, 12:30AM CST
Eli Lilly and Company (NYSE: LLY) and Adocia (Euronext Paris: FR0011184241 - ADOC) today announced a worldwide licensing collaboration focused on developing an ultra-rapid insulin, known as BioChaperone Lispro, for treatment in people with type 1 and type 2 diabetes. BioChaperone Lispro relies on Adocia's proprietary BioChaperone® technology and is currently in Phase Ib studies.
LLY: 74.43 (-0.48)
Frost & Sullivan Confers Technology Innovation Leadership Award on ADOCIA for its Robust Pipeline of Novel Therapeutic Proteins
PR Newswire Europe - Wed Nov 26, 7:00AM CST
- The company's distinctive dual strategy, devised to help it penetrate developing and developed regions, has fuelled its success
Type-1 diabetes (Juvenile Diabetes) Pipeline Review, H2 2015
M2 - Tue Feb 09, 8:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/4jtbk6/type1_diabetes) has announced the addition of the "Type-1 diabetes (Juvenile Diabetes) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type-1 diabetes (Juvenile Diabetes)and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Type-1 diabetes (Juvenile Diabetes)Overview - Therapeutics Development - Pipeline Products for Type-1 diabetes (Juvenile Diabetes)- Overview - Pipeline Products for Type-1 diabetes (Juvenile Diabetes)- Comparative Analysis - Type-1 diabetes (Juvenile Diabetes)- Therapeutics under Development by Companies - Type-1 diabetes (Juvenile Diabetes)- Therapeutics under Investigation by Universities/Institutes - Type-1 diabetes (Juvenile Diabetes)- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Type-1 diabetes (Juvenile Diabetes)- Products under Development by Companies - Type-1 diabetes (Juvenile Diabetes)- Products under Investigation by Universities/Institutes - Type-1 diabetes (Juvenile Diabetes)- Companies Involved in Therapeutics Development Companies Mentioned - 35 of the 100 Companies - 4SC AG - Adocia - AiCuris GmbH & Co. KG - Amarantus Bioscience Holdings, Inc. - Ambrx, Inc. - AntriaBio, Inc. - Aphios Corporation - Araim Pharmaceuticals Inc. - Argos Therapeutics, Inc. - Artery Therapeutics, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Athersys, Inc. - Axxam SpA - Beta-Cell NV - Biocon Limited - Biodel Inc. - Biogenomics Limited - BioLineRx, Ltd. - BioLingus AG - BioTherapeutics Inc. - Boehringer Ingelheim GmbH - Caladrius Biosciences, Inc. - Carlina Technologies SAS - Cellectis S.A. - Compugen Ltd. - Daewoong Pharmaceutical Co., Ltd. - Dance Biopharm Inc. - Diabetology (Products) Ltd - DiaMedica Inc. - Diasome Pharmaceuticals, Inc. - Dompe Farmaceutici S.p.A. - DoNatur GmbH - Effimune SAS - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/4j...1_diabetes
AMBX: (), LLY: 74.43 (-0.48), BIOD: 0.34 (-0.01), CLBS: 0.53 (-0.02), ARGS: 7.50 (+0.47), AZN: 28.96 (-0.68), CGEN: 6.62 (-0.16), ATHX: 2.35 (-0.04)
Type 2 Diabetes Therapeutics Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/82p26k/type_2_diabetes) has announced the addition of the "Type 2 Diabetes - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 2 Diabetesand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Type 2 DiabetesOverview - Therapeutics Development - Pipeline Products for Type 2 Diabetes- Overview - Pipeline Products for Type 2 Diabetes- Comparative Analysis - Type 2 Diabetes- Therapeutics under Development by Companies - Type 2 Diabetes- Therapeutics under Investigation by Universities/Institutes - Type 2 Diabetes- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Type 2 Diabetes- Products under Development by Companies - Type 2 Diabetes- Products under Investigation by Universities/Institutes - Type 2 Diabetes- Companies Involved in Therapeutics Development Companies Mentioned - Sample List - 3SBio Inc. - Addex Therapeutics Ltd - Adocia - Advinus Therapeutics Ltd. - Aegis Therapeutics, LLC - AFFiRiS AG - Alchemia Limited - Alize Pharma SAS - AlphaMab Co., Ltd - Amarantus Bioscience Holdings, Inc. - Ambrx, Inc. - Amgen Inc. - Anchor Therapeutics, Inc. - AntriaBio, Inc. - Aphios Corporation - Araim Pharmaceuticals Inc. - Arisaph Pharmaceuticals, Inc. - ArisGen SA - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Artery Therapeutics, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - AUS Bio Limited - Avaxia Biologics, Inc. - Bayer AG - Beta-Cell NV - Betagenon AB - Biocon Limited - Biodel Inc. - Biogenomics Limited - BioLingus AG - BioRestorative Therapies, Inc. - BioTherapeutics Inc. For more information visit http://www.researchandmarkets.com/research/82...2_diabetes
AMBX: (), AMGN: 156.78 (-1.22), BIOD: 0.34 (-0.01), AZN: 28.96 (-0.68), ARRY: 3.52 (-0.10)
Diabetic Foot Ulcers - Pipeline Review 2015
M2 - Wed Jan 06, 4:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/n92r2c/diabetic_foot) has announced the addition of the "Diabetic Foot Ulcers - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Foot Ulcers, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Foot Ulcers and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Develop strategic initiatives by understanding the focus areas of leading companies. - Identify and understand important and diverse types of therapeutics under development for Diabetic Foot Ulcers. - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Diabetic Foot Ulcers pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - Adocia - Aprogen, Inc. - Bayer AG - CardioVascular BioTherapeutics, Inc. - Celgene Corporation - CoDa Therapeutics, Inc. - CytoTools AG - Dipexium Pharmaceuticals LLC - EyeGene, Inc. - FirstString Research, Inc. - GlaxoSmithKline Plc - Human Stem Cells Institute - Innovaxis - Izun Pharmaceuticals Corporation - Karyopharm Therapeutics, Inc. - Lytix Biopharma AS - MediaPharma s.r.l. - MediWound Ltd. - NovaLead Pharma Pvt. Ltd. - Oneness Biotech Co., Ltd. - Osiris Therapeutics, Inc. - Plurogen Therapeutics, Inc. - Sanofi - Stratatech Corporation - TechnoPhage SA - TGV-Laboratories - Theravasc, Inc. - Tissue Med Biosciences - USV Limited For more information visit http://www.researchandmarkets.com/research/n9...betic_foot
DPRX: 11.42 (+0.11), OSIR: 5.00 (-0.05), MDWD: 8.23 (+0.11), GSK: 42.06 (-0.45), KPTI: 9.12 (-0.17), CELGZ: 1.46 (-0.04)
Global Burns Therapeutics Pipeline Review 2015
M2 - Thu Dec 03, 7:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/phkvtr/burns_pipeline) has announced the addition of the "Burns - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Burns, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Burns and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adocia - AlgiPharma AS - Biogenomics Limited - Birken AG - CytoTools AG - Destiny Pharma Limited - HanAll Biopharma Co., Ltd. - Kuros Biosurgery AG - MediWound Ltd. - Novan, Inc. - Novartis AG - Pherecydes Pharma SA - Phosphagenics Limited - Se-cure Pharmaceuticals Ltd. - Stratatech Corporation - USV Limited - Vida Therapeutics Inc. - Xiber Science GmbH For more information visit http://www.researchandmarkets.com/research/ph...s_pipeline
MDWD: 8.23 (+0.11), NVS: 80.51 (-0.88)
Venous Leg Ulcers (Crural ulcer) Pipeline Review, H2 2015 - 12 Companies & 13 Drug Profiles
M2 - Thu Oct 22, 9:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zpfjm6/venous_leg_ulcers) has announced the addition of the "Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Venous Leg Ulcers (Crural ulcer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Leg Ulcers (Crural ulcer) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adocia - CardioVascular BioTherapeutics, Inc. - CoDa Therapeutics, Inc. - CytoTools AG - FirstString Research, Inc. - Intralytix, Inc. - MacroCure Ltd. - MediWound Ltd. - Pergamum AB - RegeneRx Biopharmaceuticals, Inc. - Smith & Nephew Plc - Stratatech Corporation Drug Profiles - Biochaperone PDGF-BB - Cathelicidin - Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers - CL-05 - CODA-001 - CureXcell - CVBT-141B - EscharEx - Granexin - HP-802247 - LL-37 - RGN-137 - WPP-201 For more information visit http://www.researchandmarkets.com/research/zp...leg_ulcers
SNN: 34.19 (-0.16), MDWD: 8.23 (+0.11)
Human Insulin Market Development and Demand Forecast to 2020 - Provides Information on the Historical and Current Market Size and the Future Potential of the Market
M2 - Thu Aug 20, 5:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fhwk3w/global_industry) has announced the addition of the "Global Industry Insight: Human Insulin Market Development and Demand Forecast to 2020" report to their offering. Increasing usage of insulin pens for the administration of insulin helps to inject insulin accurately. In addition, growing demand of biosimilar drugs due to its cost effectiveness is an opportunity for the growth of the market. Human insulin market is growing moderately due to increase in prevalence of diabetic population, rise in geriatric population, rising awareness of diabetes and rising prevalence of obesity. However, strict regulatory requirements for approval of insulin and high cost of analog are inhibiting the growth of the global human insulin market. Globally, modern human insulin has the largest market share and is also the fastest growing human insulin type. In addition, long acting human insulin has the largest market share in the modern human insulin market, and premixed human insulin is the fastest growing modern human insulin in the market. Long acting human insulin is prescribed by physicians for the treatment of type 2 diabetes. Report Coverage - Provides comprehensive understanding of the market with the help of informed market outlook, opportunities, challenges, trends, size and growth, competitive analysis, major competitors and Porter analysis - Identifies the key drivers of growth and challenges of the key industry players. Also, assesses the future impact of the propellants and restraints on the market - Uncovers potential demands in the market Key Topics Covered: 1 Research Scope and Methodology 2 Executive Summary 3 Market Outlook 4 Global Market Size and Forecasts (2011 - 2020) 5 Global Market Breakdown by Type 6 Global Traditional Human Insulin Market Breakdown by Type 7 Global Modern Human Insulin Market Breakdown by Type 8 Global Market Breakdown by Brand 9 Global Market Breakdown by Region 10 Competitive Analysis and Market Share 11 Company Profiles 12 Appendix Companies Mentioned - ADOCIA - Biocon Ltd. - Bristol-Myers Squibb Company - Eli Lilly and Company - GlaxoSmithKline Plc - Julphar - Merck & Co. - Novo Nordisk A/S - Oramed Pharmaceuticals, Inc. - Pfizer, Inc. - Sanofi - TonghuaDongbao Pharmaceuticals Co., Ltd For more information visit http://www.researchandmarkets.com/research/fh...l_industry
NVO: 56.87 (-0.31), ORMP: 8.55 (+0.50), PFE: 35.31 (+0.06), MRK: 57.18 (-0.44), LLY: 74.43 (-0.48), GSK: 42.06 (-0.45), BMY: 72.73 (-0.68)
Lyonbiopole Announces Success at BIO 2015
Marketwired - Tue Jul 28, 8:02PM CDT
Lyonbiopole, leader in the life science industry, showcased at the BIO International Convention for the ninth consecutive year, celebrating an impressive delegation, influential awards and announcements, and renewed ties with partners on the American East Coast. Participants of the Lyonbiopole mission included Adocia, Alaxia, Alize Pharma, BIOASTER, CapEval Pharma, CEA Leti, Cytoo, ElsaLys Biotech, ERYtech Pharma, Eveon, Flamel Technologies, Genoway, ImmunID, Kallistem, Maat Pharma, Newtone Technologies, Orega Biotech, PDC*line Pharma, TransCure bioServices and Transgene.
Global Market Study on Human Insulin 2015-2020
M2 - Fri Jul 10, 5:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pg6w4q/global_market) has announced the addition of the "Global Market Study on Human Insulin: Asia Pacific to Witness fastest Growth by 2020" report to their offering. Modern human insulin was estimated at USD 19,526.8 million in 2014 and was expected to reach USD 40,987.1 million by 2020, growing at a CAGR of 13.2% during the forecast period. Globally, the human insulin market is witnessing significant growth due to increasing prevalence of diabetes and obesity. In addition, increasing R&D investments in drug discovery and development and rising awareness about diabetes are also driving the growth of the market. However, uneven pricing and limited access to human insulin in emerging countries and strict regulatory requirement for drug approval inhibits the growth of the market. North America has the largest market and Asia-Pacific has the fastest growing market for human insulin. In terms of type of human insulin, modern human insulin represents the largest and fastest growing segment of this market. Modern human insulin provides effective results compare to traditional human insulin. Dosages and duration of modern human insulin vary from person to person, as insulin requirement differs from person to person. Some of the major players in the human insulin market are Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Biocon, Tonghua Dongbao Pharmaceutical Co., Ltd., Adocia, Merck & Co., Inc., Pfizer, Inc., Wockhardt and others. Key Topics Covered: Chapter 1 Preface Chapter 2 Market Synopsis Chapter 3 Porter's Five Forces Analysis Chapter 4 Industry Overview Chapter 5 Global Market Size and Forecast Chapter 6 Market Size and Forecast by Type Chapter 7 Market Size and Forecast of Traditional Human Insulin by Type Chapter 8 Market Size and Forecast of Modern Human Insulin by Type Chapter 9 Market Size and Forecast by Disease Chapter 10 Market Size and Forecast by Brand Chapter 11 Market Size and Forecast by Geography Chapter 12 Pipeline Drugs for Diabetes Treatment Chapter 13 Competitive Scenario Chapter 14 Company Profiles - ADOCIA - Biocon - Bristol-Myers Squibb Company - Eli Lilly and Company - GlaxoSmithKline Plc - Julphar - Merck & Co., Inc. - Novo Nordisk A/S - Oramed Pharmaceuticals, Inc. - Pfizer, Inc. - Sanofi - Tonghua Dongbao Pharmaceutical Co., Ltd. - Wockhardt For more information visit http://www.researchandmarkets.com/research/pg...bal_market
NVO: 56.87 (-0.31), ORMP: 8.55 (+0.50), PFE: 35.31 (+0.06), MRK: 57.18 (-0.44), LLY: 74.43 (-0.48), GSK: 42.06 (-0.45), BMY: 72.73 (-0.68)
Diabetic Foot Ulcers Therapeutics Pipeline Review, H1 2015 - 30 Companies & 44 Drug Profiles
M2 - Thu Jul 09, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7tnfs3/diabetic_foot) has announced the addition of the "Diabetic Foot Ulcers - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Foot Ulcers, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Foot Ulcers and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adocia - Aprogen, Inc. - CardioVascular BioTherapeutics, Inc. - Celgene Corporation - CoDa Therapeutics, Inc. - CytoTools AG - Derma Sciences, Inc. - Dipexium Pharmaceuticals LLC - EyeGene, Inc. - FirstString Research, Inc. - GlaxoSmithKline plc - Innovaxis - Izun Pharmaceuticals Corporation - Karyopharm Therapeutics, Inc. - Kasiak Research Pvt. Ltd. - Lumosa Therapeutics Co., Ltd. - Lytix Biopharma AS - MacroCure Ltd. - MediaPharma s.r.l. - NovaLead Pharma Pvt. Ltd. - Oneness Biotech Co., Ltd. - Plurogen Therapeutics, Inc. - Reliance Life Sciences Pvt. Ltd. - Royer Biomedical, Inc. - Sanofi - Stratatech Corporation - TechnoPhage SA - Tissue Med Biosciences - USV Limited - Vyome Biosciences Private Limited For more information visit http://www.researchandmarkets.com/research/7t...betic_foot
DSCI: 3.99 (-0.03), DPRX: 11.42 (+0.11), GSK: 42.06 (-0.45), KPTI: 9.12 (-0.17), CELGZ: 1.46 (-0.04)
Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2015 Featuring 90+ Companies
M2 - Thu Jun 25, 6:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5gpct9/type_1_diabetes) has announced the addition of the "Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Type 1 Diabetes (Juvenile Diabetes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - 30 of the 93 Companies Featured - 4SC AG - ActogeniX NV - Adocia - AiCuris GmbH & Co. KG - Amarantus Bioscience Holdings, Inc. - Ambrx, Inc. - American Gene Technologies International Inc. - AntriaBio, Inc. - Argos Therapeutics, Inc. - Artery Therapeutics, Inc. - AstraZeneca PLC - Axxam SpA - Bayhill Therapeutics, Inc. - Beta-Cell NV - Biocon Limited - Biodel Inc. - Biogenomics Limited - BioLineRx, Ltd. - BioTherapeutics Inc. - Boehringer Ingelheim GmbH - Carlina Technologies SAS - Cellectis S.A. - Compugen Ltd. - Cortendo AB - CTI BioPharma Corp. - Daewoong Pharmaceutical Co., Ltd. - Diabetology Limited - DiaMedica Inc. - Diasome Pharmaceuticals, Inc. - Dompe Farmaceutici S.p.A For more information visit http://www.researchandmarkets.com/research/5g...1_diabetes
AMBX: (), CTIC: 0.44 (-0.01), BIOD: 0.34 (-0.01), ARGS: 7.50 (+0.47), AZN: 28.96 (-0.68), CGEN: 6.62 (-0.16)
Burns Pipeline Review, H1 2015 - Featuring 19 Therapeutic Companies
M2 - Thu Jun 11, 10:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l85dsl/burns_pipeline) has announced the addition of the "Burns - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Burns, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Burns and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adocia - AlgiPharma AS - Biogenomics Limited - Birken AG - CytoTools AG - Destiny Pharma Ltd. - Fibrocell Science, Inc. - HanAll Biopharma Co., Ltd. - Kasiak Research Pvt. Ltd. - Kuros Biosurgery AG - MediWound Ltd. - Novan, Inc. - Novartis AG - Se-cure Pharmaceuticals Ltd. - Stemnion, Inc - Stratatech Corporation - USV Limited - Vida Therapeutics Inc. - Xiber Science GmbH For more information visit http://www.researchandmarkets.com/research/l8...s_pipeline
FCSC: 1.24 (-0.02), MDWD: 8.23 (+0.11), NVS: 80.51 (-0.88)
Lilly to co-develop ultra-rapid insulin BioChaperone Lispro in partnership with Adocia
M2 - Fri Dec 19, 7:09AM CST
Healthcare company Eli Lilly and Company (NYSE:LLY) and Adocia (Euronext Paris:FR0011184241) jointly disclosed on Thursday a worldwide licensing collaboration to develop an ultra-rapid insulin, called BioChaperone Lispro, for treatment in people with type 1 and type 2 diabetes.
LLY: 74.43 (-0.48)
Eli Lilly reaches insulin development deal with Adocia
AP - Fri Dec 19, 6:16AM CST
INDIANAPOLIS (AP) — Eli Lilly and Co. could pay more than $570 million to French pharmaceutical company Adocia under an agreement to develop a fast-acting insulin that is in the early stages of clinical testing.
LLY: 74.43 (-0.48)
Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology
PR Newswire - Fri Dec 19, 12:30AM CST
Eli Lilly and Company (NYSE: LLY) and Adocia (Euronext Paris: FR0011184241 - ADOC) today announced a worldwide licensing collaboration focused on developing an ultra-rapid insulin, known as BioChaperone Lispro, for treatment in people with type 1 and type 2 diabetes. BioChaperone Lispro relies on Adocia's proprietary BioChaperone® technology and is currently in Phase Ib studies.
LLY: 74.43 (-0.48)
Frost & Sullivan Confers Technology Innovation Leadership Award on ADOCIA for its Robust Pipeline of Novel Therapeutic Proteins
PR Newswire Europe - Wed Nov 26, 7:00AM CST
- The company's distinctive dual strategy, devised to help it penetrate developing and developed regions, has fuelled its success
